A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
Phase 3
Active, not recruiting
NCT04488822
| Condition | Tenosynovial Giant Cell Tumor |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Daiichi Sankyo Co., Ltd. |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 40 participants |
|---|
| Interventions | Pexidartinib |
|---|
| Start date | Sep 25, 2020 |
|---|
| Completion date | Oct 27, 2021 |
|---|
| Results posted | Apr 27, 2023 |
|---|
Summary
This study will assess pexidartinib in adult participants with symptomatic TGCT that is associated with severe morbidity or functional limitations and not amendable to improvement with surgery.
Overall Response Rate (ORR) of Pexidartinib Based on RECIST 1.1 of Asian Participants With Symptomatic Tenosynovial Giant Cell Tumor (TGCT) at Week 25
At Week 25 postdose · Participants
| Pexidartinib | 0 Participants |
|---|
| Pexidartinib | 9 Participants |
|---|
| Pexidartinib | 9 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.